CA
XRTX

Clearstead Advisors’s XORTX Therapeutics XRTX Stock Holding History

Clearstead Advisors’s Portfolio XRTX Stock Details XRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$92 Hold
55
– – ﹤0.01% 2199
2025
Q4 		$156 Hold
55
– – ﹤0.01% 2453
2025
Q3 		$225 Hold
55
– – ﹤0.01% 2848
2025
Q2 		$251 Hold
55
– – ﹤0.01% 2555
2025
Q1 		$266 Hold
55
– – ﹤0.01% 2115
2024
Q4 		$313 Hold
55
– – ﹤0.01% 2009
2024
Q3 		$455 Hold
55
– – ﹤0.01% 1959
2024
Q2 		$527 Hold
55
– – ﹤0.01% 1930
2024
Q1 		$696 Hold
55
– – ﹤0.01% 1433
2023
Q4 		$640 Buy
55
+43
+358% +$3.17K ﹤0.01% 1441
2023
Q3 		$3K Buy
12
+6
+100% +$1.57K ﹤0.01% 1343
2023
Q2 		$1.62K Hold
6
– – ﹤0.01% 1192
2023
Q1 		$1.16K Hold
6
– – ﹤0.01% 1214
2022
Q4 		$2.02K Hold
6
– – ﹤0.01% 1091
2022
Q3 		$3K Buy
+6
New +$3.38K ﹤0.01% 1057

Other funds holding XRTX

KWM
Kingsview Wealth Management Grants Pass, Oregon $7.33B AUM 16.07% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return

Clearstead Advisors's XRTX Position: Q1 2026 in Review

Clearstead Advisors held its XORTX Therapeutics (XRTX) position steady in Q1 2026 at 55 shares worth $92. The position accounts for ﹤0.01% of the portfolio, ranked #2199.

Clearstead Advisors first reported a position in XRTX in Q3 2022 and has held it in 15 quarters since. The position peaked at $3K in Q3 2023. 3 funds tracked by Wall St. Rank hold XRTX as of Q1 2026.

  • Clearstead Advisors held 55 shares of XORTX Therapeutics worth $92 as of Q1 2026.
  • Clearstead Advisors left its XORTX Therapeutics share count unchanged in Q1 2026.
  • XORTX Therapeutics made up ﹤0.01% of Clearstead Advisors's portfolio in Q1 2026, its #2199 holding.
  • Clearstead Advisors first reported a position in XORTX Therapeutics in Q3 2022 and has held it in 15 quarters since.
  • Clearstead Advisors's XORTX Therapeutics position peaked at $3K in Q3 2023.
  • 3 funds tracked by Wall St. Rank held XORTX Therapeutics as of Q1 2026.

Based on Clearstead Advisors's 13F filing for Q1 2026, filed 6 May 2026.